IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

ANTONARELLI, GABRIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.626
AS - Asia 1.315
NA - Nord America 1.151
Continente sconosciuto - Info sul continente non disponibili 124
SA - Sud America 109
AF - Africa 21
OC - Oceania 12
Totale 4.358
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.090
DE - Germania 1.027
SG - Singapore 373
CN - Cina 364
IT - Italia 234
BD - Bangladesh 173
HK - Hong Kong 137
SE - Svezia 109
VN - Vietnam 88
BR - Brasile 75
IN - India 74
RU - Federazione Russa 73
FR - Francia 56
NL - Olanda 30
CA - Canada 29
ID - Indonesia 28
FI - Finlandia 27
GB - Regno Unito 21
IE - Irlanda 16
AR - Argentina 13
JP - Giappone 13
TR - Turchia 13
PH - Filippine 11
PL - Polonia 11
MX - Messico 10
AU - Australia 8
KR - Corea 8
JM - Giamaica 7
AT - Austria 6
CI - Costa d'Avorio 6
CO - Colombia 6
TW - Taiwan 6
ZA - Sudafrica 6
SA - Arabia Saudita 5
SV - El Salvador 5
EC - Ecuador 4
NZ - Nuova Zelanda 4
PK - Pakistan 4
BE - Belgio 3
CL - Cile 3
CR - Costa Rica 3
ES - Italia 3
IQ - Iraq 3
UZ - Uzbekistan 3
BO - Bolivia 2
EG - Egitto 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MY - Malesia 2
PA - Panama 2
PE - Perù 2
RO - Romania 2
SC - Seychelles 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UA - Ucraina 2
VE - Venezuela 2
AL - Albania 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CY - Cipro 1
DK - Danimarca 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
JO - Giordania 1
KE - Kenya 1
LB - Libano 1
MD - Moldavia 1
MQ - Martinica 1
NP - Nepal 1
OM - Oman 1
PY - Paraguay 1
SR - Suriname 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.235
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 992
Ashburn 202
Singapore 175
Hong Kong 125
Santa Clara 101
San Jose 96
Council Bluffs 74
Los Angeles 63
Hefei 61
Beijing 54
New York 45
Milan 44
Dallas 42
Hanoi 32
Bengaluru 30
Boardman 29
Buffalo 22
Ho Chi Minh City 22
Shanghai 22
Lauterbourg 21
Chandler 20
Helsinki 19
Hyderabad 18
Moscow 18
Jakarta 17
Dublin 16
Naples 16
Rome 13
Guangzhou 11
Munich 11
Boston 10
Cangzhou 10
Chennai 10
Florence 10
Tokyo 10
Chicago 9
Istanbul 9
Oklahoma City 7
Orem 7
São Paulo 7
Warsaw 7
Abidjan 6
Charlotte 6
Denver 6
Nuremberg 6
Rho 6
Seattle 6
Wuhan 6
Bari 5
Bologna 5
Düsseldorf 5
Lappeenranta 5
Paris 5
Quanzhou 5
San Salvador 5
Sydney 5
Atlanta 4
Bến Tre 4
Haiphong 4
Huizhou 4
Miano 4
Montreal 4
Newark 4
Ranchi 4
Roubaix 4
Seoul 4
Tianjin 4
Toronto 4
Baghdad 3
Belmont 3
Brasília 3
Brescia 3
Brooklyn 3
Da Nang 3
Dammam 3
Dhaka 3
Fuzhou 3
Gainesville 3
Islamabad 3
Johannesburg 3
Manila 3
Mexico City 3
Nanjing 3
Palermo 3
Pasadena 3
Phoenix 3
Pittsburgh 3
Portsmouth 3
Princeton 3
Redmond 3
Reggio Emilia 3
Rio de Janeiro 3
San Diego 3
San Francisco 3
Santiago 3
St Louis 3
Taipei 3
Tashkent 3
The Dalles 3
Turku 3
Totale 2.733
Salva come PNG Salva come JPEG
Nome #
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure 350
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 286
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population 258
Systemic Treatment of Ductal Carcinoma In Situ of the Breast 254
Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group 216
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 215
The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers 207
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population 201
Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies 192
An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer 184
Therapeutic Cancer Vaccines Revamping: Technology Advancements and Pitfalls 182
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy 164
Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review 156
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 152
COVID-19 related risk in patients enrolled in early-phase clinical trials 151
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? 149
Harmonizing PD-L1 testing in metastatic triple negative breast cancer 149
Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development 143
Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67? 140
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population 132
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study 108
Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation 97
Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer 96
Extendeond Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients 35
Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study 22
Targeting brain metastases in breast cancer 19
From Dose-Finding to Dose-Optimization in Early-Phase oncology clinical trials 16
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study 14
Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards 14
Redefining clinical trial strategic design to support drug approval in medical oncology 12
Emerging treatment landscape of non-muscle invasive bladder cancer 12
Tumor infiltrating lymphocytes across breast cancer subtypes: current issues for biomarker assessment 11
Beyond PD(L)-1 blockade in microsatellite-instable cancers: current landscape of immune co-inhibitory receptor targeting 10
Targeting cellular components of the tumor microenvironment in solid malignancies 8
Pembrolizumab and oral metronomic cyclophosphamide in patients with chest wall breast cancer (PERICLES): an immune-biomarker analysis of tumor infiltrating lymphocytes (TILs) and programmed cell death ligand protein 1 (PD-L1) 3
Totale 4.358
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.012
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.012
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202250 0 0 1 4 9 4 9 11 5 3 2 2
2022/2023111 8 12 19 10 10 22 6 1 6 2 9 6
2023/2024954 15 17 29 33 70 51 155 120 58 121 143 142
2024/2025954 116 129 123 105 55 26 16 54 41 70 74 145
2025/20261.977 198 168 162 149 105 56 241 97 149 107 253 292
2026/2027312 124 186 2 0 0 0 0 0 0 0 0 0
Totale 4.358